Sexually Transmitted Infection Transmission Dynamics During the Coronavirus Disease 2019 (COVID-19) Pandemic Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men

Christina M. Schumacher, Nicole Thornton, Jessica Wagner, Carla Tilich, Khalil G. Ghanem, Matthew M. Hamilt, Carl Latkin, Anne Rompalo, Sebastian Ruhs, Adena Greenbaum, and Jacky M. Jennings

Background. The impact of coronavirus disease 2019 (COVID-19) mitigation measures on sexually transmitted infection (STI) transmission and racial disparities remains unknown. Our objectives were to compare sex and drug risk behaviors, access to sexual health services, and STI positivity overall and by race during the COVID-19 pandemic compared with pre-pandemic among urban sexual minority men (MSM).

Methods. Sexually active MSM aged 18–45 years were administered a behavioral survey and STI testing every 3-months. Participants who completed at least 1 during-pandemic (April 2020–December 2020) and 1 pre-pandemic study visit (before 13 March 2020) that occurred less than 6 months apart were included. Regression models were used to compare during- and pre-pandemic visit outcomes.

Results. Overall, among 231 MSM, reports of more than 3 sex partners declined (pandemic-1: adjusted prevalence ratio 0.68; 95% confidence interval: .54–.86; pandemic-2: 0.65, .51–.84; pandemic-3: 0.57, .43–.75), substance use decreased (pandemic-1: 0.75, .61–.75; pandemic-2: 0.62, .50–.78; pandemic-3: 0.61, .47–.80), and human immunodeficiency virus/preexposure prophylaxis care engagement (pandemic-1: 1.20, 1.07–1.34; pandemic-2: 1.24, 1.11–1.39; pandemic-3: 1.30, 1.16–1.47) increased. STI testing decreased (pandemic-1: 0.68, .57–.81; pandemic-2: 0.78, .67–.92), then rebounded (pandemic-3: 1.01, .87–1.18). Neither Chlamydia (pandemic-2: 1.62, .75–3.46; pandemic-3: 1.13, .24–1.27) nor gonorrhea (pandemic-2: 0.87, .46 1.62; pandemic-3: 0.56, .24–1.27) positivity significantly changed during vs pre-pandemic. Trends were mostly similar among Black vs. non-Black MSM.

Conclusions. We observed sustained decreases in STI risk behaviors but minimal change in STI positivity during compared with pre-pandemic. Our findings underscore the need for novel STI prevention strategies that can be delivered without in-person interactions.

Keywords. COVID-19 pandemic; sexually transmitted infections; MSM.
opportunities for decreased transmission. Emergency orders that closed or restricted attendance in public spaces, such as bars and clubs, may have decreased attendance and, therefore, opportunities for important subgroups such as gay, bisexual, and other men who have sex with men (MSM) to meet new and usual sex partners, thus limiting mixing between infected and susceptible MSM and decreasing transmission [16–20]. Several studies among MSM have reported substantial declines in the reported number of sex partners during the pandemic [10, 21–26]. Others reported increased or no change in the number of sex partners and variability over the pandemic time period [10, 27, 28]. Additionally, substance use, specifically methamphetamine use, has previously been associated with STI and HIV risk among MSM [29–31]. Though data are limited, at least 2 studies showed decreased reported illicit drug use among MSM during compared with pre-pandemic [23, 32], while another reported similar proportions of MSM reporting decreased and increased drug use during the pandemic [21].

Our goal was to provide insight into changes in STI transmission dynamics during the COVID-19 pandemic among MSM and, specifically, among Black MSM who suffer extremely disproportionate STI and HIV infection burdens [33–35] to ensure appropriate intervention. The objectives were to examine trends in sexual and drug risk behaviors (ie, number/type of partners, substance use), access to sexual health services (ie, care engagement, testing), and STI positivity (ie, chlamydia, gonorrhea) overall and by race before and during the COVID-19 pandemic among 1 urban MSM cohort.

METHODS

Overview

The Understanding Sexual Health in Networks study is a prospective cohort study focused on elucidating the network epidemiology of syphilis among MSM to inform and strengthen local health department syphilis prevention programs. The Johns Hopkins School of Medicine Institutional Review Board (IRB) approved this study.

Study Population

Participants were recruited from 2 health department sexual health clinics, a federally qualified health center (FQHC), a community-based LGBTQ+ organization, community engagement events, and respondent driven sampling (RDS). Eligibility criteria included male sex at birth and gender identity, aged 18–45 years, residence with a Baltimore City zip code, reporting sex with a man (past 6 months), and willingness and ability to give informed consent for the study. Participants were enrolled between 20 July 2018 and 14 February 2020 and followed every 3 months for up to 2 years. This analysis included information from participants who attended any study visit during the COVID-19 pandemic, defined as any study visit that occurred after 13 March 2020, and who attended at least 1 study visit prior to 13 March 2020 within 6 months of their first “pandemic visit.” Up to 3 visits that occurred during the pandemic until 31 December 2020 were included.

Pre-Pandemic and Pandemic Study Visits

Pre-pandemic study visits included an audiocomputer self-assisted interview (ACASI) behavioral survey, a face-to-face network interview of recent sex partners, and biologic testing for syphilis and chlamydia/gonorrhea at 3 anatomic sites (urogenital, rectal, oropharyngeal). During the pandemic, interviewers administered ACASI and network interviews via telephone or virtual platform (ie, Zoom). Study visits, including interviews and biologic testing, were suspended on 13 March 2020 due to enactment of pandemic remote-work policies at the Johns Hopkins University. Interviewing resumed on 2 April 2020, once the IRB approved remote study visit protocols. Chlamydia/gonorrhea testing resumed on 23 June 2020 through use of at-home self-testing kits. Participants were mailed triple site chlamydia/gonorrhea testing kits upon completion of their study interview. Kits included detailed instructions on how to collect specimens as well as instructions and materials to mail specimens to the Johns Hopkins University laboratory. Syphilis testing was suspended throughout the observation period for this analysis.

Study visits that occurred on or before 13 March 2020 were categorized as pre-pandemic. To examine changes over time and in alignment with timing of follow-up visits, pandemic visits were categorized based on the visit date as pandemic-1 (April 2020–June 2020), pandemic-2 (July 2020 –September 2020), and pandemic-3 (October 2020–December 2020).

Measures

Participants were questioned regarding activities during the prior 3 months. Outcomes included the number and type of sex partners, substance use, access to sexual healthcare, and STI positivity.

We examined the reported number of total, new, and casual sex partners. Binary variables were created using the median reported pre-pandemic value as a cut point (total: more than 3 sex partners; new: more than 2 sex partners; and casual: more than 2 sex partners).

Substance use risk was defined as reporting use of any substance and, separately, methamphetamine in response to either of the following questions: “In the past 3 months, which of the following drugs did you use?” and “Have you used any of the following before or during sex in the past 3 months?” Response options included crack/cocaine, methamphetamine (eg, crystal, tina, meth, speed), heroin, prescription painkillers, downers, psychedelics, and party drugs (eg, ecstasy, E, Molly, MDMA, GHB, Special K, or poppers).
Access to sexual healthcare included the following 2 measures: HIV or PrEP care engagement and STI testing. Care engagement was defined as self-reported attendance (in-person or telemedicine) to a routine HIV (if living with HIV) or PrEP (if not living with HIV) care visit or currently taking antiretroviral medication for HIV/PrEP. STI testing was defined as self-report of any STI testing (past 3 months) that was not related to study visits.

For both chlamydia and gonorrhea, positivity was defined as a positive nucleic acid amplification test at any anatomic site for each study visit when biologic testing was available (pre-pandemic, pandemic-2, and pandemic-3).

Demographics (ie, race) were collected at baseline. Race was dichotomized as Black/non-Black. HIV status was confirmed through HIV laboratory testing or medical record documentation and ascertained during the pre-pandemic study visit.

Statistical Analyses
Descriptive statistics were used to examine changes in each outcome across all 4 time periods overall and by race. A series of regression models was performed to estimate the likelihood of reporting outcomes at each during-pandemic visit compared with pre-pandemic. Generalized estimating equations with modified Poisson regression (ie, with robust standard errors) were used to account for repeated measures within individuals and to correct for overestimation of prevalence ratios with nonrare binary outcomes. All models were adjusted for the reported value of the specific outcome at the pre-pandemic visit. Regression models stratified by race also were generated. Analyses were performed using Stata version 15.1 (Stata Corp, College Station, TX).

RESULTS
Study Population
Among 567 individuals screened, 74.4% (422) were eligible, among whom 98.8% (417 of 422) were enrolled in the cohort. Among these, 55.4% (231 of 417) met this analysis’s inclusion criteria. At baseline, participants in the analytic cohort (vs those excluded) were similar by race, age, HIV status, syphilis history, reported number of sex partners, and substance use but were significantly more likely to be recruited from the sexual health clinics (28.1% vs 14.3%), report HIV/PrEP care engagement (61.9% vs 48.9%), and report any nonstudy-related STI test (93.9% vs 86.5%).

Among participants included in the analytic cohort, 96.1% (222 of 231) completed a pandemic-1 visit, 84.0% (194 of 231) completed a pandemic-2 visit, including 9 who missed a pandemic-1 visit, and 61.9% (143 of 231) completed a pandemic-3 visit. Pre-pandemic characteristics of participants who completed study follow-up (8.2%, 19 of 231) or were lost to follow-up (29.9%, 69 of 231) were similar to those retained during pandemic-3. Overall, 73.6% (170 of 231) were Black/African American, 60.6% (140 of 231) had completed high school, and 35.9% (83 of 231) reported they were not currently working. The median age was 31 years (interquartile range, 19–47), and 31.6% (73 of 231) were aged 24–29 years. A plurality was recruited through RDS (39.4% 91 of 231), followed by the sexual health clinics (28.1%, 65 of 231) and the FQHC (23.4%, 54 of 231). At the pre-pandemic visit, 37.7% (87 of 231) were living with HIV and 41.3% (95 of 231) had a history of syphilis infection.

Changes in Reported Number of Sex Partners
The number of reported total, new, and casual sex partners in the past 3 months declined during the pandemic; these declines were sustained over time. The median number of total sex partners declined from 2 (range, 0–75) pre-pandemic to 1 during all 3 pandemic periods (pandemic-1: 1, 0–25; pandemic-2: 1, 0–20; pandemic-3: 1, 0–20). Sustained declines in the proportion reporting more than 3 total sex partners, multiple new partners, and multiple casual partners were observed (Table 1). Among Black MSM, the median number of total sex partners (pre-pandemic: 1, 0–75; pandemic-1: 1, 0–25; pandemic-2: 1, 0–20; pandemic-3: 1, 0–20) and the proportion reporting multiple casual sex partners were similar over time.

Regression models showed statistically significant decreased likelihood in reporting more than 3 total sex partners during compared with pre-pandemic (pandemic-1: adjusted prevalence ratio [aPR], 0.68; 95% confidence interval [CI]: .54–.86; pandemic-2: aPR, 0.65; 95% CI: .51–.84; pandemic-3: aPR, 0.57; 95% CI: .43–.75; Table 1). Similar declines in reports of multiple new partners over time were observed. Participants were less likely to report multiple casual partners during compared with pre-pandemic; associations only were significant during pandemic-1.

Black MSM were less likely to report more than 3 sex partners and multiple new sex partners (total partners pandemic-1: aPR, 0.82; 95% CI: .62–1.07; pandemic-2: aPR, 0.71; 95% CI: .52–.97; pandemic-3: aPR, 0.53; 95% CI: .37–.78 and new partners pandemic-1: aPR, 0.72; 95% CI: .55–.93; pandemic-2: aPR, 0.65; 95% CI: .48–.89; pandemic-3: aPR, 0.53; 95% CI: .35–.80) but similarly likely to report multiple casual partners during compared with pre-pandemic. Non-Black MSM were significantly less likely to report more than 3 total sex partners, multiple new partners, and multiple casual partners during each pandemic period (vs pre-pandemic).

Changes in Reported Substance Use
Reported use of hard substances was consistently lower during compared with pre-pandemic (pandemic-1: aPR, 0.75; 95% CI: .61–.92; pandemic-2: aPR, 0.62; 95% CI: .50–.78; pandemic-3: aPR, 0.61; 95% CI: .47–.80; Table 2). Reported methamphetamine use declined during compared with pre-pandemic but only was statistically significant during pandemic-3 (pandemic-1: aPR,
### Table 1. Reported Number of Sex Partners (Past 3 Months) Among MSM Before and During the Coronavirus Disease 19 Pandemic

|                     | Reported More Than 3 Total Sex Partners | Reported More Than 2 New Sex Partners | Reported More Than 2 Casual Sex Partners |
|---------------------|----------------------------------------|---------------------------------------|-----------------------------------------|
|                     | N           | n   | %   | aPR* | 95% CI      | N           | n   | %   | aPR* | 95% CI      | N           | n   | %   | aPR* | 95% CI      |
| Overall             |            |     |     |      |            |              |     |     |      |            |              |     |     |      |            |              |
| Pre-pandemic        | 231        | 77  | 33.3|  Ref  |            | 84           | 36.4|  Ref  |            | 83           | 35.9|  Ref  |            |            |              |
| Pandemic-1          | 222        | 53  | 23.9| 0.68  | (.54–.86)   | 51           | 23.0| 0.64  | (.51–.81)   | 61           | 27.5| 0.74  | (.60–.92)   |            |              |
| Pandemic-2          | 194        | 42  | 21.7| 0.65  | (.51–.84)   | 44           | 22.7| 0.65  | (.50–.83)   | 56           | 28.9| 0.82  | (.66–1.02)  |            |              |
| Pandemic-3          | 143        | 29  | 20.3| 0.57  | (.43–.75)   | 27           | 18.9| 0.53  | (.38–.74)   | 44           | 30.8| 0.82  | (.63–1.04)  |            |              |
| Black MSM           |            |     |     |      |            |              |     |     |      |            |              |     |     |      |            |              |
| Pre-pandemic        | 170        | 47  | 27.6|  Ref  |            | 55           | 32.4|  Ref  |            | 48           | 28.2|  Ref  |            |            |              |
| Pandemic-1          | 161        | 39  | 24.2| 0.82  | (.62–1.07)  | 36           | 22.4| 0.72  | (.55–.93)   | 44           | 27.3| 0.91  | (.70–1.18)  |            |              |
| Pandemic-2          | 141        | 28  | 19.8| 0.71  | (.52–.97)   | 29           | 20.6| 0.65  | (.48–.89)   | 38           | 27.0| 0.96  | (.72–1.27)  |            |              |
| Pandemic-3          | 105        | 17  | 16.2| 0.53  | (.37–.78)   | 17           | 16.2| 0.53  | (.35–.80)   | 30           | 28.6| 0.93  | (.68–1.27)  |            |              |
| Non-Black MSM       |            |     |     |      |            |              |     |     |      |            |              |     |     |      |            |              |
| Pre-pandemic        | 66         | 30  | 49.2|  Ref  |            | 29           | 47.5|  Ref  |            | 34           | 55.7|  Ref  |            |            |              |
| Pandemic-1          | 161        | 14  | 23.0| 0.47  | (.30–.73)   | 15           | 24.6| 0.52  | (.32–.84)   | 17           | 27.9| 0.50  | (.34–.74)   |            |              |
| Pandemic-2          | 53         | 14  | 26.4| 0.56  | (.36–.88)   | 15           | 28.3| 0.62  | (.40–.97)   | 18           | 34.0| 0.62  | (.43–.90)   |            |              |
| Pandemic-3          | 38         | 12  | 31.6| 0.62  | (.41–.95)   | 10           | 26.3| 0.53  | (.30–.95)   | 14           | 36.8| 0.65  | (.43–.97)   |            |              |

Among gay, bisexual and other men who have sex with men participating in the Understanding Sexual Health in Networks Study, Baltimore, Maryland, December 2019 - December 2020. Pandemic-1: April 2020–June 2020; pandemic-2: July 2020–September 2020; pandemic-3: October 2020–December 2020.

Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; MSM, men who have sex with men.

* Prevalence ratios calculated using generalized estimating equations and Poisson regression with robust standard errors to account for repeated measures among individuals and adjusting for reported value during the pre-pandemic study visit. Bolded values are significant using \( P < .05 \).

0.81; 95% CI: .57–1.16; pandemic-2: aPR, 0.88; 95% CI: .62–1.26; pandemic-3: aPR, 0.84; 95% CI: .75–.95.

Compared with pre-pandemic, fewer Black and non-Black MSM reported using any hard substances during the pandemic. These decreases were statistically significant or borderline significant. Reported methamphetamine use also was less frequent during compared with pre-pandemic but was not statistically significant among Black MSM. Regression models for

### Table 2. Reported Substance Use (Past 3 Months Among Gay, Bisexual, and Other Men Who Have Sex With Men Overall and By Race Before and During the Coronavirus Disease 19 Pandemic, Understanding Sexual Health in Networks Study, Baltimore City, Maryland, December 2019–December 2020

|                     | Any Substance Use | Methamphetamine Use |
|---------------------|-------------------|---------------------|
|                     | N         | n   | %   | aPR* | 95% CI      | N         | n   | %   | aPR* | 95% CI      |
| Overall             |            |     |     |      |            |            |     |     |      |            |              |
| Pre-pandemic        | 231        | 98  | 42.4|  Ref  |            | 22         | 9.5|  Ref  |            |            |              |
| Pandemic-1          | 222        | 70  | 31.5| 0.75  | (.61–.92)   | 17         | 7.7| 0.81  | (.57–1.16)  |            |              |
| Pandemic-2          | 194        | 51  | 26.3| 0.62  | (.50–.78)   | 13         | 6.7| 0.88  | (.62–1.26)  |            |              |
| Pandemic-3          | 143        | 38  | 26.6| 0.61  | (.47–.80)   | 6          | 4.2| 0.84  | (.75–.95)   |            |              |
| Black MSM           |            |     |     |      |            |              |     |     |      |            |              |
| Pre-pandemic        | 170        | 67  | 39.4|  Ref  |            | 18         | 10.6|  Ref  |            |            |              |
| Pandemic-1          | 161        | 48  | 29.8| 0.77  | (.60–.99)   | 12         | 7.5| 0.71  | (.45–1.11)  |            |              |
| Pandemic-2          | 141        | 33  | 23.4| 0.58  | (.43–.78)   | 11         | 7.8| 0.73  | (.50–1.07)  |            |              |
| Pandemic-3          | 105        | 24  | 22.9| 0.58  | (.42–.80)   | 5          | 4.8| 0.60  | (.35–1.04)  |            |              |
| Non-Black MSM       |            |     |     |      |            |              |     |     |      |            |              |
| Pre-pandemic        | 66         | 31  | 50.8|  Ref  |            | 4          | 6.6|  …    |  …   |            |  …          |
| Pandemic-1          | 61         | 22  | 36.1| 0.71  | (.51–.99)   | 5          | 8.2|  …    |  …   |            |  …          |
| Pandemic-2          | 53         | 18  | 34.0| 0.72  | (.52–1.00)  | 2          | 3.8|  …    |  …   |            |  …          |
| Pandemic-3          | 38         | 14  | 36.8| 0.68  | (.44–1.06)  | 1          | 2.6|  …    |  …   |            |  …          |

Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; MSM, men who have sex with men.

* Any use of methamphetamine (eg, crystal, meth, tina, speed, party drugs, cocaine/crack, heroin, prescription painkillers, downers, psychedelics, including use before or during sex in the past 3 months.

* Prevalence ratios calculated using generalized estimating equations and Poisson regression with robust standard errors to account for repeated measures among individuals and adjusting for reported value during the pre-pandemic study visit. Regression models for methamphetamine use among non-Black MSM are not presented due to small sample sizes. Bolded values are significant using \( P < .05 \).
methamphetamine use among non-Black MSM were not performed due to small sample sizes.

**Changes in Reported Access to Sexual Healthcare**

Overall, reported HIV/PrEP care engagement significantly increased during the pandemic (pandemic-1: aPR, 1.15; 95% CI: 1.05–1.25; pandemic-2: aPR, 1.16; 95% CI: 1.06–1.26; pandemic-3: aPR, 1.22; 95% CI: 1.11–1.33; Table 3). STI testing significantly decreased during pandemic-1 and pandemic-2 but was similar to pre-pandemic levels during pandemic-3 (pandemic-1: aPR, 0.68; 95% CI: .57–.81; pandemic-2: aPR, 0.78; 95% CI: .67–.92; pandemic-3: aPR, 1.01; 95% CI: .87–1.18).

Reported HIV/PrEP care engagement significantly increased among Black MSM during the pandemic (pandemic-1: aPR, 1.20; 95% CI: 1.07–1.34; pandemic-2: aPR, 1.24; 95% CI: 1.11–1.39; pandemic-3: aPR, 1.30; 95% CI: 1.16–1.47). No significant changes in care engagement were observed among non-Black MSM. Reported STI testing trends among Black and non-Black MSM were similar to those observed overall.

**Changes in STI Positivity**

Pre-pandemic, 75.3% (174 of 231) of participants were tested at a study visit for chlamydia/gonorrhea, among whom 6.9% (12 of 174) and 15.5% (27 of 174) were chlamydia and gonorrhea positive, respectively (Table 4). During pandemic-2, 67.0% of participants were tested (130 of 194). Among these, 9.2% (12 of 130) were chlamydia positive and 16.9% (22 of 130) were gonorrhea positive. During pandemic-3, 60.1% (86 of 143) were tested, among whom 8.1% (7 of 86) were chlamydia positive and 7.0% (86 of 86) were gonorrhea positive. Regression models revealed no statistically significant differences in chlamydia or gonorrhea positivity over time.

Time trends in chlamydia and gonorrhea positivity were generally similar among Black vs non-Black MSM. However, chlamydia and gonorrhea positivity was substantially higher among Black compared with non-Black MSM.

**DISCUSSION**

Among this MSM cohort, we found evidence of significant and sustained decreased sexual risk behavior (measured by number and type of sex partners), any substance use, and STI testing, and increased HIV/PrEP care engagement during the pandemic. Among those tested, no significant differences in chlamydia or gonorrhea positivity were observed during compared with pre-pandemic.

Important differences in risk behavior change by race were observed. Notably, among Black MSM, we observed no change in the median total number of sex partners and no change in the likelihood of reporting multiple casual sex partners during compared with pre-pandemic. In contrast, declines in all 3 sex partner measures were observed among non-Black MSM. No substantial differences by race in trends in substance use, sexual healthcare access, and STI positivity were observed.

---

**Table 3. Reported Access to Sexual Health Services (Past 3 Months) Among Gay, Bisexual, and Other Men Who Have Sex With Men Overall and By Race Before and During the Coronavirus Disease 2019 Pandemic, Understanding Sexual Health in Networks Study, Baltimore City, Maryland December 2019–December 2020**

|                        | Engaged in Preexposure Prophylaxis Care (if Not Living With HIV) or HIV Care (if Living With HIV) | Received More Than 1 Nonstudy-Related Sexually Transmitted Infection Test* |
|------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                        | N       | n     | %     | aPR*    | 95% CI    | n     | %     | aPR*    | 95% CI    |
| Overall               |         |       |       |         |           |       |       |         |           |
| Pre-pandemic          | 231     | 140   | 60.6  | Ref     |           | 134   | 58.0  | Ref     |           |
| Pandemic-1            | 222     | 154   | 70.3  | 1.15    | (1.05–1.25)| 87    | 39.2  | 0.68    | (0.57–0.81)|
| Pandemic-2            | 194     | 138   | 71.5  | 1.16    | (1.06–1.26)| 90    | 46.4  | 0.78    | (0.67–0.92)|
| Pandemic-3            | 143     | 106   | 74.3  | 1.22    | (1.11–1.33)| 82    | 57.3  | 1.01    | (0.87–1.18)|
| Black MSM             |         |       |       |         |           |       |       |         |           |
| Pre-pandemic          | 170     | 97    | 57.0  | Ref     |           | 101   | 59.4  | Ref     |           |
| Pandemic-1            | 161     | 109   | 67.7  | 1.20    | (1.07–1.34)| 68    | 42.2  | 0.72    | (0.60–0.86)|
| Pandemic-2            | 141     | 102   | 72.3  | 1.24    | (1.11–1.39)| 70    | 49.6  | 0.82    | (0.69–0.96)|
| Pandemic-3            | 105     | 77    | 73.3  | 1.30    | (1.16–1.47)| 61    | 58.1  | 1.03    | (0.87–1.23)|
| Non-Black MSM         |         |       |       |         |           |       |       |         |           |
| Pre-pandemic          | 61      | 43    | 70.5  | Ref     |           | 33    | 54.1  | Ref     |           |
| Pandemic-1            | 61      | 45    | 73.8  | 1.05    | (0.94–1.17)| 19    | 31.1  | 0.58    | (0.39–0.86)|
| Pandemic-2            | 53      | 36    | 67.9  | 0.97    | (0.84–1.12)| 20    | 37.7  | 0.70    | (0.46–1.06)|
| Pandemic-3            | 38      | 29    | 76.3  | 1.03    | (0.91–1.16)| 21    | 55.3  | 0.97    | (0.70–1.34)|

Pandemic-1: April 2020–June 2020; pandemic-2: July 2020–September 2020; pandemic-3: October 2020–December 2020. Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men.

*Includes any sexually transmitted infection test (syphilis, gonorrhea/chlamydia, HIV) in the past 3 months excluding those performed as part of study visits.

*Prevalence ratios calculated using generalized estimating equations and Poisson regression with robust standard errors to account for repeated measures among individuals and adjusting for reported value during the pre-pandemic study visit. Bolded values are significant using P < .05.
Table 4. Chlamydia and Gonorrhea Positivity (Past 3 Months) Among Gay, Bisexual, and Other Men Who Have Sex With Men Overall and By Race Before and During the Coronavirus Disease 2019 Pandemic, Understanding Sexual Health in Networks Study, Baltimore City, Maryland December 2019–December 2020

|                        | Chlamydiaa |             |             | Gonorrheaa |             |             |
|------------------------|------------|-------------|-------------|------------|-------------|-------------|
|                        | N          | n           | %           | aPR        | 95% CI      | N          | n           | %           | aPR        | 95% CI      |
| Overall                |            |             |             |            |             |             |             |             |            |             |
| Pre-pandemic           | 174        | 12          | 6.9%        | Ref        |             | 27          | 15.5%       |             | Ref        |             |
| Pandemic-2             | 130        | 12          | 9.2%        | 1.62       | (.75–3.46)  | 22          | 16.9%       | 0.87        | (.46–1.62)  |
| Pandemic-3             | 86         | 7           | 8.1%        | 1.13       | (.24–1.27)  | 6           | 7.0%        | 0.56        | (.24–1.27)  |
| Black MSM              |            |             |             |            |             |             |             |             |            |             |
| Pre-pandemic           | 125        | 10          | 8.0%        | Ref        |             | 24          | 19.2%       |             | Ref        |             |
| Pandemic-2             | 87         | 10          | 11.5%       | 1.83       | (.81–4.13)  | 18          | 20.7%       | 0.88        | (.45–1.72)  |
| Pandemic-3             | 66         | 6           | 9.1%        | 1.11       | (.45–2.73)  | 5           | 7.6%        | 0.53        | (.21–1.35)  |
| Non-Black MSM          |            |             |             |            |             |             |             |             |            |             |
| Pre-pandemic           | 49         | 2           | 4.1%        | ...        | ...         | 3           | 6.1%        | ...         | ...        |
| Pandemic-2             | 43         | 2           | 4.7%        | ...        | ...         | 4           | 9.3%        | ...         | ...        |
| Pandemic-3             | 20         | 1           | 5.0%        | ...        | ...         | 1           | 5.0%        | ...         | ...        |

Pandemic-1: April 2020–June 2020; pandemic-2: July 2020–September 2020; pandemic-3: October 2020–December 2020.

Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; MSM, men who have sex with men.

*Among those tested via a nucleic acid amplification test at any anatomic site. Biologic testing was unavailable during the first 3 study visits that occurred during the pandemic (April 2020–June 2020).

Prevalence ratios calculated using generalized estimating equations and Poisson regression with robust standard errors to account for repeated measures among individuals and adjusting for reported value during the pre-pandemic study visit. Regression models for chlamydia and gonorrhea positivity among non-Black MSM are not shown due to small sample sizes. Bolded values are significant using P < .05.

Findings that showed sustained decreases in the reported number of sex partners and substance use among MSM during the COVID-19 pandemic corroborate some prior studies [10, 21, 23–26, 28] and contrast others that found declines in sexual behaviors early in the pandemic followed by increases over time [10, 28]. Our findings also confirm prior work showing decreased STI testing during the pandemic [5, 8, 9]; however, we observed a rebound to pre-pandemic levels in STI testing in late 2020. Findings from prior studies may not be directly comparable with the findings herein. Most other studies were conducted primarily among White MSM during the pandemic’s early stages while the strictest emergency orders were in effect, and several recruited participants solely through online platforms. Nonetheless, this study supports previous evidence that COVID-19 mitigation measures temporarily decreased population-level STI/HIV risk behaviors and access to STI testing.

Surprisingly, we found increased, rather than decreased, HIV/PrEP care [10–12]. This could be attributable to selection biases (participants retained in the study are also those likely to be engaged in HIV/PrEP care). Possibly, implementation of alternative modalities for healthcare delivery (ie, telemedicine) may have removed barriers to HIV/PrEP care retention for some. Future work should examine the impact of telemedicine on HIV/PrEP care retention.

This study also provides information on STI positivity during the pandemic, for which data have been limited. One MSM cohort study in Amsterdam reported small but significant declines in bacterial STI diagnoses during compared with pre-pandemic [23]. Another study of at-home STI testing in 1 New York City PrEP clinic reported chlamydia and gonorrhea positivity similar to our findings and no change in pre- and during-pandemic positivity [36]. Three studies reported increased chlamydia and 2 reported increased gonorrhea positivity during the pandemic, but these increases were in the context of decreased testing volumes, and increased positivity may be an artifact of shifts toward testing symptomatic individuals [8, 9, 37].

Findings from this and other studies suggest that, among MSM, the impact of COVID-19 mitigation measures on transmission has been limited. One explanation is that the impact of decreased number of sex partners was sufficient to offset, but not overcome, the impact of increased prevalence of untreated infections due to disruptions to clinical and prevention services, as one modeling study suggested [38]. In this cohort, a substantial proportion (28%–31%) of participants continued to report multiple casual partners during the pandemic (vs 36% pre-pandemic), which likely facilitated ongoing transmission. Similarly, despite declines in the number and type of sex partners, underlying sexual network structures that facilitate STI transmission (ie, partner concurrency, network density) [39] may not have been sufficiently altered. This may be particularly true for networks of Black MSM, among whom we observed fewer and smaller declines in the number of sex partners and higher pre-pandemic STI positivity (vs non-Black MSM). Future work will examine sexual network characteristics and their relationship to STI positivity during compared with pre-pandemic.

There are several limitations to this study. Administering biologic testing during the pandemic has been extremely challenging. Sample sizes for chlamydia/gonorrhea results were
limited because a substantial proportion of testing kits were not returned. Results may overestimate positivity if symptomatic participants differentially returned testing kits and may underestimate positivity if those at highest acquisition risk differentially did not return kits. Information on symptoms consistent with chlamydia/gonorrhea was not ascertained, which is an important limitation. However, our test kit return rates were consistent with prior work utilizing mailed testing kits [40], and characteristics of those tested (vs those not tested) were similar. Syphilis testing did not resume until early 2021, and future work will explore syphilis trends. Observed decreases in reported behaviors over time may reflect preexisting trends [41] or may be attributed to participation in a research study [42, 43], social desirability bias, and/or attrition bias. We believe social desirability and attrition biases were minimal. During the pandemic, interviewers administered surveys, while ACASI surveys were used pre-pandemic. However, pre-pandemic, interviewers routinely obtained sensitive information through network interviews and had well-established rapport with participants. Participants who completed study follow-up were similar to those lost to follow-up, and sensitivity analyses restricted to participants who attended all 4 study visits showed similar results. Finally, this study population was drawn from a convenience sample in 1 city; therefore, results may not be generalizable to all MSM in this or other urban settings.

This analysis provides important information on longitudinal trends in sexual behaviors, substance use, access to sexual healthcare and STI positivity among MSM throughout the pandemic. Promisingly, HIV/PrEP care engagement and STI testing appeared to improve over time, and we found no evidence that racial STI disparities were exacerbated. Concerns remain regarding potential increased STI transmission during and post pandemic among MSM and, specifically, Black MSM, given continued diversion of clinical and public health staff to pandemic response and restrictions on in-person clinical evaluations. Our findings of sustained decreases in STI risk behaviors during compared with pre-pandemic without evidence of decreased STI positivity underscores the urgent need for frequent STI testing and treatment in this population. Research to evaluate novel strategies (ie, increased implementation of at-home testing kits, providing medication to sex partners, less invasive testing) to deliver STI/HIV services without in-person interactions is needed.

Notes

Financial support. This work was supported by the US Centers for Disease Control and Prevention (1U01PS005171-01).

Potential conflicts of interest. M. H. reports personal fees from Roche Molecular Diagnostics (consulting) and GlaxoSmithKline (consulting); honorarium from BMJ Best Practices and Clinical Care for educational activities; and royalties from UpToDate outside the submitted work. A. R. reports personal fees from UpToDate and participation on a data safety monitoring board for an National Institutes of Health-funded study and an advisory board for the American Sexually Transmitted Disease Association. All remaining authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Menza TW, Garai J, Ferrer J, Hecht J. Rapid uptake of home-based HIV self-testing during social distancing for SARS-CoV-2 infection in Oregon. AIDS Behav 2021; 25:167–70.
2. Johnson KA, Burghardt NO, Tang EC, et al. Measuring the impact of the COVID-19 pandemic on sexually transmitted diseases public health surveillance and program operations in the state of California. Sex Transm Dis 2021; 48:606–13.
3. Crane MA, Popovic A, Stolbach AI, Ghanem KG. Reporting of sexually transmitted infections during the COVID-19 pandemic. Sex Transm Infect 2021; 97:101–2.
4. Blank S. Impact of COVID-19 on STI services, New York City. 2020. 2020 STD Prevention Conference. Virtual; 2020.
5. Berzkalns A, Thibault CS, Barbic LA, Golden MR, Ksorsroupor C, Kerani RP. Decreases in reported sexually transmitted infections during the time of COVID-19 in King County, WA: decreased transmission or screening? Sex Transm Dis 2021; 48(85):544–9.
6. Pagaoo M, Grey J, Torrone E, Kreisel K, Stenger M, Weinstock H. Trends in nationally notifiable sexually transmitted disease case reports during the US COVID-19 pandemic, January to December 2020. Sex Transm Dis 2021; 48:798–804.
7. Tao J, Napoleon SC, Maynard MA, et al. Impact of the COVID-19 pandemic on sexually transmitted infection clinic visits. Sex Transm Dis 2021; 48:e5–7.
8. Bonett S, Petits D, Dowshen N, Bauermeister J, Wood SM. The impact of the COVID-19 pandemic on sexually transmitted infection/human immunodeficiency virus testing among adolescents in a large pediatric primary care network. Sex Transm Dis 2021; 48:e91–e3.
9. Pinto CN, Niles JK, Kaufman HW, et al. Impact of the COVID-19 pandemic on chlamydia and gonorrhea screening in the U.S. Am J Prev Med 2021; 61:386–93.
10. Pampati S, Emrick K, Siegler AJ, Jones J. Changes in sexual behavior, PrEP adherence, and access to sexual health services because of the COVID-19 pandemic among a cohort of PrEP-using MSM in the South. J Acquir Immune Defic Syndr 2021; 87:639–43.
11. Santos GM, Ackerman B, Rao A, et al. Economic, mental health, HIV prevention and HIV treatment impacts of COVID-19 and the COVID-19 response on a global sample of cisgender gay men and other men who have sex with men. AIDS Behav 2021; 25:311–21.
12. Kalichman SC, Eaton LA, Berman M, et al. Intersecting pandemics: impact of SARS-CoV-2 (COVID-19) protective behaviors on people living with HIV, Atlanta, Georgia. J Acquir Immune Defic Syndr 2020; 85:66–72.
13. Baran O, Akyac A. The effect of fear of covid-19 transmission on male sexual behaviour: a cross-sectional study. Int J Clin Pract 2021; 75:e13889.
14. Bachmann LH, Bolan G. Dear Colleague Letter: Shortage of STI Diagnostic Tests and Laboratory Supplies. Online, 2020 September 8, 2020. Available at: https://www.cdc.gov/std/general/DCL-Diagnostic-Test-Shortage.pdf. Accessed 30 August 2021.
15. National Coalition of STD Directors. COVID-19 & the State of the STD Field: Phase III, 2021 January 2021. Available at: https://www.ncsddc.org/resource/covid-19-and-the-state-of-the-std-field-phase-iii/. Accessed 30 August 2021.
16. Dudareva-Viruale S, Haar K, Sailer A, et al. Prevalence of pharyngeal and rectal Chlamydia trachomatis and Neisseria gonorrhoeae infections among men who have sex with men in Germany. Sex Transm Infect 2014; 90:46–51.
17. Burns PA, Mena LA, Crosby RL. Forecasting the future: predicting STI diagnosis and its implications for ending the HIV epidemic among black men who have sex with men. J Urban Health 2020; 97:642–52.
18. Patel RR, Luke DA, Proctor EK, et al. Sex venue-based network analysis to identify HIV prevention dissemination targets for men who have sex with men. LGBT Health 2018; 5:78–85.
19. Jennings JM, Tchao C, Meza B, et al. Overlapping transmission networks of early syphilis and/or newly HIV diagnosed gay, bisexual and other men who have sex with men (MSM): opportunities for optimizing public health interventions. AIDS Behav 2020; 24:2895–905.
20. Wohl DA, Khan MR, Tisdale C, et al. Locating the places people meet new sexual partners in a southern US city to inform HIV/STI prevention and testing efforts. AIDS Behav 2011; 15:283–91.
21. Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the impact of COVID-19 on men who have sex with men across the United States in April, 2020. AIDS Behav 2020; 24:2024–32.

Sexually transmitted infection transmission dynamics • CID 2022;75 (1 July) • e1143
2. McKay T, Henne J, Gonzales G, Garvelic KA, Quares R, Gallegos SG. Sexual behavior change among gay and bisexual men during the first COVID-19 pandemic wave in the United States. Sex Res Social Policy 2021; 1–15.

3. van Bilsen WPH, Zimmermann HML, Boyd A, et al. Sexual behavior and its determinants during COVID-19 restrictions among men who have sex with men in Amsterdam. J Acquir Immune Defic Syndr 2021; 86:288–96.

4. Edelman NL, Nutland W, Witzel TC, Samba P, Nadarzynski T. COVID-19 anxiety and sexual behavior among male and gender diverse people who have sex with men (MGDPSM) during England’s first lockdown. STI & HIV 2021 World Congress Virtual, 2021.

5. Chow EPF, Hocking JS, Ong JJ, et al. Brief report: changes in PrEP use, sexual practice, and use of face mask during sex among MSM during the second wave of COVID-19 in Melbourne, Australia. J Acquir Immune Defic Syndr 2021; 86:153–6.

6. Starks TJ, Jones SS, Sauermilch D, et al. Evaluating the impact of COVID-19: a cohort comparison study of drug use and risky sexual behavior among sexual minority men in the U.S.A. Drug Alcohol Depend 2020; 216:108260.

7. Stephenson R, Chavanduka TMD, Rosso MT, et al. Sex in the time of COVID-19: results of an online survey of gay, bisexual and other men who have sex with men’s experience of sex and HIV prevention during the US COVID-19 epidemic. AIDS Behav 2021; 25:40–8.

8. Spahnie M, Matthews A, Kiss D, et al. Changes in sexual behavior during COVID-19 among men who have sex with men in a sexual network study. STI & HIV 2021 World Congress Virtual 2021.

9. Jennings JM, Wagner J, Tilechin C, et al. Methamphetamine use, syphilis, and specific online sex partner meeting venues are associated with HIV status among urban black gay and bisexual men who have sex men. Sex Transm Dis 2021; 48:532–59.

10. Hoernig M, Challion A, Moore DJ, Morris SM, Smith DM, Little SJ. Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. J Acquir Immune Defic Syndr 2016; 71:551–7.

11. Grewal R, Allen VG, Gardner S, et al. Serosorting and recreational drug use are risk factors for diagnosis of genital infection with chlamydia and gonorrhoea among HIV-positive men who have sex with men: results from a clinical cohort in Ontario, Canada. Sex Transm Infect 2017; 93:71–5.

12. Kalichman S, Mathews G, Banas E, Kalichman M. HIV status disclosure and sexual transmission risks among people who are living with HIV and receiving treatment for non-HIV sexually transmitted infections, Cape Town, South Africa. J Acquir Immune Defic Syndr 2020; 83:223–9.

13. de Vos A, Kidd S, Grey JA, et al. State-specific rates of primary and secondary syphilis among men who have sex with men—United States, 2015. MMWR Morb Mortal Wkly Rep 2017; 66:349–54.

14. Stenger MR, Pathela P, Anschuetz G, et al. Increases in the rate of Neisseria gonorrhoeae among gay, bisexual and other men who have sex with men—findings from the Sexually Transmitted Disease Surveillance Network 2010–2015. Sex Transm Dis 2017; 44:393–7.

15. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol 2017; 27:238–43.

16. Carnevale C, Richards P, Cohall R, et al. At-home testing for sexually transmitted infections during the COVID-19 pandemic. Sex Transm Dis 2021; 48:e11–e4.

17. Hill BJ, Anderson B, Lock L. Chlamydial infection among adolescents and young adults receiving sexual and reproductive health care during the COVID-19 pandemic. Sex Transm Dis 2021; 48:e11–e4.

18. Jenness SM, Le Guillou A, Chandra C, et al. Projected HIV and bacterial sexually transmitted infection incidence following COVID-19-related sexual distancing and clinical service interruption. J Infect Dis 2021; 223:1019–28.

19. Rothenberg R. Maintenance of endemicity in urban environments: a hypothesis linking risk, network structure and geography. Sex Transm Infect 2007; 83:10–5.

20. Norelli J, Zlotorzynska M, Sanchez T, Sullivan PS. Scaling up carekit: lessons learned from expansion of a centralized home HIV and sexually transmitted infection testing program. Sex Transm Dis 2021; 48:666–70.

21. Curtis L. Sexual activity rates are declining both before and during the covid 19 tragedy. Sex Transm Dis 2021; doi:10.1097/OLQ.0000000000001589.